Rxo (RXO) Payables (2021 - 2026)

Rxo (RXO) has reported Payables for 6 consecutive years, with $584.0 million the latest figure, recorded in Q1 2026.

• Payables for Q1 2026 came in at $584.0 million, up 17.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $584.0 million (up 17.27% YoY), and the FY2025 annual result was $539.0 million, down 5.11% from the prior year.
• Payables was $584.0 million for Q1 2026 at Rxo, up from $539.0 million in the prior quarter.
• Over five years, Payables peaked at $584.0 million in Q1 2026 and troughed at $372.0 million in Q1 2024.
• Average Payables over 5 years is $486.3 million, with a median of $496.0 million recorded in 2023.
• The widest YoY moves for Payables: up 37.2% in 2024, down 25.0% in 2024.
• Over 5 years, Payables stood at $501.0 million in 2022, then fell by 17.37% to $414.0 million in 2023, then jumped by 37.2% to $568.0 million in 2024, then slipped by 5.11% to $539.0 million in 2025, then gained by 8.35% to $584.0 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $584.0 million in Q1 2026, $539.0 million in Q4 2025, and $481.0 million in Q3 2025.